Bioventus, a global leader in orthobiologic solutions, is launching OSTEOMATRIX+, its next generation biphasic bone graft for use in bone remodeling in a variety of orthopaedic and spine applications. OSTEOMATRIX+ is a moldable bone graft substitute consisting of bovine collagen and biphasic, hydroxyapatite/ß-tricalcium phosphate granules designed to produce a reliable, porous scaffold and sustained osteoconductivity throughout the bone remodeling process.
The Bioventus research and development group led a cross functional team to develop OSTEOMATRIX+ which has more unique handling properties, including improved moldability, flexibility and versatility, than its predecessor.
“OSTEOMATRIX+ represents the first of several next generation products that will be added to the Bioventus portfolio in the next five years,” said Tony Bihl, CEO, Bioventus. “We will provide more diverse orthobiologic offerings for hospitals and efficacious solutions for both surgeons and their patients, as we continue to grow and serve these markets.”
